NovoCure Limited
NVCRNASDAQHealthcare● Active
$17.53
+$0.37(+2.16%)
Market Cap$2.0B
P/E Ratio—
52W High$19.25
52W Low$9.82
NovoCure Limited (NVCR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVCR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.62
Est. -$0.51 · -21.1%
Revenue
$0.17B
Est. $0.17B · +3.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
NVCR reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | -$0.30 | — | — | — | $0.17B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$0.51 | -$0.62 | -21.1% | $0.17B | $0.17B | +3.8% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.41 | -$0.22 | +46.3% | $0.17B | $0.17B | -0.0% |
| ▲ Q4 FY2025 | Oct 30, 2025 | -$0.42 | -$0.33 | +21.4% | $0.17B | $0.17B | -4.1% |
| ▲ Q3 FY2025 | Jul 24, 2025 | -$0.39 | -$0.36 | +7.7% | $0.16B | $0.16B | +0.0% |
| ▲ Q2 FY2025 | Apr 24, 2025 | -$0.47 | -$0.31 | +34.0% | $0.15B | $0.15B | +0.7% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.34 | -$0.61 | -79.4% | $0.16B | $0.15B | +9.3% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.34 | -$0.28 | +17.6% | $0.16B | $0.15B | +1.3% |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
-$0.30
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$0.62
EPS Est.
-$0.51
EPS Surpr.
-21.1%
Revenue
$0.17B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.41
EPS Surpr.
+46.3%
Revenue
$0.17B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.42
EPS Surpr.
+21.4%
Revenue
$0.17B
Q3 FY2025
Jul 24, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.39
EPS Surpr.
+7.7%
Revenue
$0.16B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
-$0.31
EPS Est.
-$0.47
EPS Surpr.
+34.0%
Revenue
$0.15B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$0.61
EPS Est.
-$0.34
EPS Surpr.
-79.4%
Revenue
$0.16B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.28
EPS Est.
-$0.34
EPS Surpr.
+17.6%
Revenue
$0.16B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.27 | $-0.27 | $-0.26 | 1 |
| Q3 FY2027 | $-0.28 | $-0.28 | $-0.27 | 1 |
| Q2 FY2027 | $-0.31 | $-0.30 | $-0.30 | 1 |
| Q1 FY2027 | $-0.32 | $-0.31 | $-0.31 | 1 |
| Q4 FY2026 | $-0.32 | $-0.32 | $-0.31 | 1 |
| Q3 FY2026 | $-0.42 | $-0.33 | $-0.22 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -21.1% | $11.93 | $15.21 | +27.49% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +46.3% | $14.99 | $13.75 | -8.27% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +21.4% | $13.48 | $12.82 | -4.90% |
| ▲ Q3 FY2025 | Jul 24, 2025 | +7.7% | $16.51 | $12.54 | -24.05% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +34.0% | $17.77 | $18.55 | +4.39% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -79.4% | $21.96 | $19.23 | -12.43% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +17.6% | $16.89 | $16.99 | +0.59% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +22.5% | $18.79 | $18.65 | -0.75% |
Q2 FY2026+27.49%
Report Date
Apr 30, 2026
EPS Beat/Miss
-21.1%
Price Before
$11.93
Price After
$15.21
Q1 FY2026-8.27%
Report Date
Feb 26, 2026
EPS Beat/Miss
+46.3%
Price Before
$14.99
Price After
$13.75
Q4 FY2025-4.90%
Report Date
Oct 30, 2025
EPS Beat/Miss
+21.4%
Price Before
$13.48
Price After
$12.82
Q3 FY2025-24.05%
Report Date
Jul 24, 2025
EPS Beat/Miss
+7.7%
Price Before
$16.51
Price After
$12.54
Q2 FY2025+4.39%
Report Date
Apr 24, 2025
EPS Beat/Miss
+34.0%
Price Before
$17.77
Price After
$18.55
Q1 FY2025-12.43%
Report Date
Feb 27, 2025
EPS Beat/Miss
-79.4%
Price Before
$21.96
Price After
$19.23
Q4 FY2024+0.59%
Report Date
Oct 30, 2024
EPS Beat/Miss
+17.6%
Price Before
$16.89
Price After
$16.99
Q3 FY2024-0.75%
Report Date
Jul 25, 2024
EPS Beat/Miss
+22.5%
Price Before
$18.79
Price After
$18.65
Avg Beat Reaction-5.50%
Avg Miss Reaction+7.53%
Beat Rate6 / 8 quarters
Largest Move+27.49% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVCR ends December
NovoCure Limited (NVCR) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.62 — missing the analyst consensus of $-0.51 by -21.1%. The next NVCR earnings date is expected around September 1, 2026.
Each quarter, investors track NVCR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVCR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVCR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVCR earnings · 5 questionsNovoCure Limited's next earnings report is expected around September 1, 2026. NVCR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVCR historically reports after market close (AMC).
NVCR earnings datewhen is NVCR earningsNVCR next earnings datewhen does NVCR report earningsNVCR earnings calendar
▸ Source: FMP · NovoCure Limited SEC filings · US GAAP · NovoCure Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026